Lung aspergillosis in renal cell carcinoma patient treated with sunitinib

QJM: An International Journal of Medicine

Volumn 105, Issue 7, 2012, Pages 689-692

  Visvardis, E E ^a   Gao, F ^a   Paes, M N ^b   Duprez, O ^a   Waxman, J ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ITRACONAZOLE; SUNITINIB;

AGED; ARTICLE; ASPERGILLUS; BRONCHUS OBSTRUCTION; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COUGHING; DIGESTIVE SYSTEM ULCER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FIBEROPTIC BRONCHOSCOPY; FUNGUS HYPHAE; HEMOPTYSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; LUNG ANGIOGRAPHY; LUNG ASPERGILLOSIS; LUNG COLLAPSE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 84863769677     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr091     Document Type: Article

References (44)

1. Yao Z, Liao W. Fungal respiratory disease. Curr Opin Pulm Med 2006; 12:222-7.
2. Latge JP. Aspergillus Fumingatus and Aspergillosis. Clin Microbiol Rev 1999; 12:410-50.
3. Silveira F, Paterson DL. Pulmonary fungal infections. Curr Opin Pulm Med 2005; 11:242-6.
4. Balloy V, Chignard M. The innate immune response to Aspergillus Fumingatus. Microbes Infect 2009; 11:919-27.
5. Jersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus Fumingatus cellular stage. J Immunol 2006; 176:3717-24.
6. Martinon F, Mayor A, Tschopp J. The inflammasoms: guardians of the body. Annu Rev Immunol 2009; 27:229-65.
7. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 2009; 1143:1-20.
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
9. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 2002; 111:927-30.
10. Netea MG, Warris A, Van der Meer JW, Fenton MJ, Verver-Janssen TJ, Jacobs LE, et al. Aspergillus Fumingatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003; 188:420-26.
11. Simitsopoulou M, Roilidis E, Likartsis C, Ioannidis J, Orfanou A, Paliognianni F, et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus Fumingatus. Antimicrob Agents Chemother 2007; 51:1048-54.
12. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2004; 173:589-94.
13. Harizi H, Gualde N. The impact of eicosanoids on the cross-talk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 2005; 65:507-14.
14. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary Aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100:345-51.
15. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspaces and processing of pro-IL-beta. Mol Cell 2002; 10:417-26.
16. Inohara Chamaillaird, Mc Donald C, Nuñez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74:355-83.
17. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. Kryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-32.
18. Chow LQM, Eckhartdt SG. Sunitinib: from rationale design to clinical efficacy. J Clin Oncol 2007; 25:884-94.
19. Faivre S, Dimitri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734-45.
20. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumour cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13.
21. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of sugnal tranducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 2002; 168:762-5.
22. Wu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105.
23. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S. Regulation of the innate and adaptive immune responses by Stat3 signaling in tumour cells. Nat Med 2004; 10:48-54.
24. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of Stat3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51.
25. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010; 21(Suppl. 1):S3-11.
26. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009; 284:6038-42.
27. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27.
28. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009; 21:10-6.
29. Sutterwala FS, Flavell RA. NLRC4/IPAF: a CARD carrying member of the NLR family. Clin Immunol 2009; 130:2-6.
30. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13.
31. Vonk AG, Netea MG, van Krieken JH, Iwakura Y, van der Meer JW, Kullberg BJ. Endogenous interleukin (IL)-1 alpha and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 2006; 193:1419-26.
32. Said-Sadier N, Padilla E, Langsley G, Ojcius DM. Aspergillus fumigatus stimulates the NLRP3 inflammas ome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS One 2010; 5:e10008.
33. Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Wevers B, Bruijns SC, et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol 2009; 10:203-13.
34. Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long term response data for 255 patients with metastatic renal cell carcinoma. Treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410-11.
35. Mc Dermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized phase-III trial of high-dose interleukin-2 versus subcutaneous interleukin and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41.
36. Motzer RJ, Bachik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-96.
37. Coppin C, Porzolt F, Autenrith M. Immunotherapy for advanced renal cell cancer (review). Cochrane Database Syst Rev 2004, Issue 2.
38. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13:1367-73.
39. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
40. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24.
41. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10:757-63.
42. Grazziutti ML, Rex JH, Cowart RE, Anaissie EJ, Ford A, Savary CA, et al. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997; 176:1579-83.
43. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/ lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA 2010; 107:2902-7.
44. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. Identification of known drugs that act as inhibitors of NF-kB signaling and their mechanism of action. Biochem Pharmacol 2010; 79:1272-80.